Cancer: Leading Causes of Death: Death Rates, Leading Causes of Death Among Minority Groups, U.S., National Institutes of Health (NIH) National Heart, Lung, and Blood Institute 2005-2012 (2002-2010)

——————————————————————
Source: Vital Statistics of the United States, NCHS
======================================
Cancer (2nd) – Leading Causes of Death: Death Rates, U.S. Per 100,000
——————————————————————
2010☝186.2 (2012)
2008👇186 (2011)
2007☝ 186.6 (2010)
2007*👇185.7 (2009)
2006*👇187.1 (2008)
2005*☝188.7 (2007)
2004👇168.6 (2006)
2003☝189.3 (2005)
======================================
Leading Causes of Death Among Minority Groups, U.S.: Cancer
——————————————————————
BlackPercent of All Deaths
——————————————————————
2010☝23% (2nd highest, behind heart: 24.1%) (2012)
2008 – 22.1% (
2nd highest, behind heart: 24.5%) (2011)
2007☝22.1% (
2nd highest, behind heart: 24.6%) (2010)
2006☝21.75% (
2nd highest, behind heart: 24.92%) (2009)
2005👇21.6% (
2nd highest, behind heart: 25.3%) (2008)
2004☝21.8% (
2nd highest, behind heart: 25.8%) (2007)
2003☝21.5% (
2nd highest, behind heart: 26.6%) (2006)
2002☝21% (
2nd highest, behind heart: 27%) (2005)
——————————————————————
HispanicPercent of All Deaths
——————————————————————
2010☝21.5% – (highest) (2012)
2008👇20.7% (
2nd highest, behind heart: 20.8%) (2011)
2007☝20.8% (
2nd highest, behind heart: 21.8%) (2010)
2006☝20.02% (
2nd highest, behind heart: 21.74%) (2009)
2005👇19.9% (
2nd highest, behind heart: 22.5%) (2008)
2004☝20% (
2nd highest, behind heart: 22.7%) (2007)
2003 – 19.7% (
2nd highest, behind heart: 23.2%) (2006)
2002☝19.7% (
2nd highest, behind heart: 23.9%) (2005)
——————————————————————
Asian*Percent of All Deaths – * Includes deaths among individuals of Asian extraction and Asian-Pacific Islanders
——————————————————————
2010👇27.70% – (highest) (2012)
2008☝28.7% (
highest, before heart: 24.8%) (2011)
2007☝27.6% (
highest, before heart: 23.6%) (2010)
2006☝26.36% (
highest, before heart: 23.87%) (2009)
2005👇25.7% (
highest, before heart: 24.2%) (2008)
2004☝26.8% (
highest, before heart: 24.6%) (2007)
2003☝26.2% (
highest, before heart: 25.3%) (2006)
2002☝25.4% (
2nd highest, behind heart: 26.4%) (2005)
——————————————————————
American Indian**Percent of All Deaths – ** Includes deaths among Aleuts and Eskimos
American Indian/Alaska Native
——————————————————————
2010☝19% – (highest) (2012)
2008☝18.5 (
highest, before heart: 18.%) (2011)
2007☝18.2% (
2nd highest, behind heart: 18.9%) (2010)
2006👇17.43% (
2nd highest, behind heart: 19.49%) (2009)
2005👇17.7% (
2nd highest, behind heart: 19.1%) (2008)
2004☝18.2% (
2nd highest, behind heart: 19.8%) (2007)
2003👇16.4% (
2nd highest, behind heart: 20.6%) (2006)
2002☝18% (
2nd highest, behind heart: 20.1%) (2005)
======================================
REFERENCES:
======================================
2010 (2012):
——————————————————————
http://www.nhlbi.nih.gov/about/factpdf.htm
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/toc.htm
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/FactBook2012.pdf
——————————————————————
2010 – Black (2012):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/chapter4data.htm#gr9-121
——————————————————————
2010 – Hispanic (2012):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/chapter4data.htm#gr9-122
——————————————————————
2010 – Asian/Pacific Islander (2012):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/chapter4data.htm#gr9-123
——————————————————————
2010 – American Indian/Alaska Native (2012):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook/chapter4data.htm#gr9-124
======================================
2005-2011 Archive (2002-2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factpdf_archive.htm
======================================
2011 – Fiscal Year – NHLBI Fact Book Archive (2008-2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4.htm
——————————————————————
PDF:
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/FactBook_2011.pdf
——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers)
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/toc.htm
——————————————————————
2008 – Leading Causes of Death: Death Rates, U.S. (2011):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4data.htm#gr8
——————————————————————
2008 – Black (2011):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4data.htm#gr9-121
——————————————————————
2008 – Hispanic (2011):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4data.htm#gr9-122
——————————————————————
2008 – Asian (2011):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4data.htm#gr9-123
——————————————————————
2008 – American Indian (2011):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-11/chapter4data.htm#gr9-124
======================================
2010 – Fiscal Year – NHLBI Fact Book (2007-2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4.htm
——————————————————————
PDF:
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/FactBook_2010.pdf
——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers)
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/toc.htm
——————————————————————
2007 – Leading Causes of Death: Death Rates, U.S. (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr8
——————————————————————
2007 (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr9-121
——————————————————————
2007 – Black (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr9-121
——————————————————————
2007 – Hispanic (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr9-122
——————————————————————
2007 – Asian (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr9-123
——————————————————————
2007 – American Indian (2010):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-10/chapter4data.htm#gr9-124
======================================
2009 – Fiscal Year – NHLBI Fact Book (2006-2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4.htm
——————————————————————
PDF:
——————————————————————
http://www.nhlbi.nih.gov/about/FactBook2009_final.pdf
——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/toc.htm
——————————————————————
2007* – Leading Causes of Death: Death Rates, U.S., *Data for 2007 are preliminary (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4data.htm#gr8
——————————————————————
2006 – Leading Causes of Death Among Minority Groups, U.S. (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4.htm
——————————————————————
2006 – Black (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4data.htm#gr9-121
——————————————————————
2006 – Hispanic (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4data.htm#gr9-122
——————————————————————
2006 – Asian (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4data.htm#gr9-123
——————————————————————
2006 – American Indian (2009):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-09/chapter4data.htm#gr9-124
======================================
2008 – Fiscal Year – NHLBI Fact Book (2005-2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4.htm
——————————————————————
PDF:
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/FactBookFinal.pdf
——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/toc.htm
——————————————————————
2006* – Leading Causes of Death: Death Rates, U.S., *Data for 2006 are preliminary (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4.htm#gr8
——————————————————————
2005 – Leading Causes of Death Among Minority Groups, U.S. (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4.htm
——————————————————————
2005 – Leading Causes of Death Among Minority Groups, U.S. (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4.htm
——————————————————————
2005 – Black (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4data.htm#gr9-121
——————————————————————
2005 – Hispanic (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4data.htm#gr9-122
——————————————————————
2005 – Asian (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4data.htm#gr9-123
——————————————————————
2005 – American Indian (2008):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-08/chapter4.htm
======================================
2007 – Fiscal Year – NHLBI Fact Book (2004-2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4.htm
——————————————————————
PDF:
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/07factbk.pdf
——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/toc.htm
——————————————————————
2005* – Leading Causes of Death: Death Rates, U.S., *Data for 2005 are preliminary (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4data.htm#gr8
——————————————————————
2004 – Leading Causes of Death Among Minority Groups, U.S. (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4.htm
——————————————————————
2004 – Black (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4data.htm#gr9-121
——————————————————————
2004 – Hispanic (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4.htm#gr9-124
——————————————————————
2004 – Asian (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4data.htm#gr9-123
——————————————————————
2004 – American Indian (2007):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-07/chapter4data.htm#gr9-124
======================================
2006 – Fiscal Year – NHLBI Fact Book (2003-2004):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4.htm
——————————————————————
PDF:
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/06factbk.pdf
——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/toc.htm
——————————————————————
2004 – Leading Causes of Death: Death Rates, U.S. (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm#gr8
——————————————————————
2003 – Leading Causes of Death Among Minority Groups, U.S. (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4.htm#gr9-12
——————————————————————
2003 – Black (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm#gr9-12
——————————————————————
2003 – Hispanic (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm#gr9-12
——————————————————————
2003 – Asian (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm#gr9-12
——————————————————————
2003 – American Indian (2006):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm#gr9-12
======================================
2005 – Fiscal Year – NHLBI Fact Book (2002-2003):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4.htm
——————————————————————
PDF:
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/05factbk.pdf
——————————————————————
HTML/Web Version (Accessible version, recommended for screen readers):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/toc.htm
——————————————————————
2003 – Leading Causes of Death: Death Rates, U.S. (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr8
——————————————————————
2002 – Leading Causes of Death Among Minority Groups, U.S. (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr9-12
——————————————————————
2002 – Black (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr9-12
——————————————————————
2002 – Hispanic (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr9-12
——————————————————————
2002 – Asian (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr9-124
——————————————————————
2002 – American Indian (2005):
——————————————————————
http://www.nhlbi.nih.gov/about/factbook-05/chapter4data.htm#gr9-12
======================================

Count de Money: What Are the Costs of Cancer ? (American Cancer Society Cancer Facts & Figures 2002-2013)

======================================
What Are the Costs of Cancer?
——————————————————————
National Institutes of Health (NIH) estimates:
——————————————————————
overall costs of cancer:
——————————————————————
2010 – $263.8 billion (2011)
2010☝$263.8 billion (2010)

2008👇$201.5 billion (2013)
2008☝$228.1 billion (2009)
2007☝$226.8 billion (2012)
2007☝$219.2 billion (2008)

2006👇$206.3 billion (2007)
2005☝$209.9 billion (2006)
2004☝$189.8 billion (2005)
2003☝$189.5 billion (2004)
2002☝$171.6 billion (2003)
2001☝$156.7 billion (2002)

——————————————————————
direct medical costs
(total of all health expenditures)
——————————————————————
2010 – $102.8 billion (2011)
2010☝$102.8 billion (2010)

2008👇$77.4 billion (2013)
2008👇$93.2 billion (2009)
2007☝$103.8 billion (2012)
2007☝$89.0 billion (2008)
2006☝$78.2 billion (2007)
2005☝$74.0 billion (2006)
2004☝$69.4 billion (2005)
2003☝$64.2 billion (2004)
2002☝$60.9 billion (2003)
2001☝$56.4 billion (2002)

——————————————————————
2008-2011 – indirect morbidity costs
(cost of lost productivity due to illness)
——————————————————————
2010 – $20.9 billion (2011)
2010☝$20.9 billion (2010)
2008☝$18.8 billion (2009)
2007☝$18.2 billion (2008)
2006☝$17.9 billion (2007)
2005☝$17.5 billion (2006)
2004☝$16.9 billion (2005)
2003☝$16.3 billion (2004)

2002👇$15.5 billion (2003)
2001☝$15.6 billion (2002)
——————————————————————
indirect mortality costs
(cost of lost productivity due to premature death)
——————————————————————
2010 – $140.1 billion (2011)
2010☝$140.1 billion (2010)
2008☝$124.0 billion (2013)

2008👇$116.1 billion (2009)
2007☝$123.0 billion (2012)
2007☝$112.0 billion (2008)

2006👇$110.2 billion (2007)
2005☝$118.4 billion (2006)
2004👇$103.5 billion (2005)
2003☝$109 billion (2004)
2002☝$95.2 billion (2003)
2001☝$84.7 billion (2002)

——————————————————————
According to US Census Bureau:
——————————————————————
Americans uninsured
2012-2013 had no health insurance coverage
——————————————————————
2010👇approximately 50 million (2013)
2009 – almost 51 million (2012)
2009☝almost 51 million (2011)
2008☝46 million (2010)
——————————————————————
2008 – approximately 28% aged 18 to 34 years (2010)
——————————————————————
2010👇almost one-third of Hispanics (31%) (2013)
2009 – almost one-third of Hispanics (32%) (2012)
2009☝almost one­-third of Hispanics (32%) (2011)
——————————————————————
2011-2012 (17 years of age and younger)
2010-2012had no health insurance coverage
——————————————————————
2010 – one in 10 children (2013)
2009 – one in 10 children (2012)
2009 – one in 10 children (2011)
2008 – 10% of children (2010)
——————————————————————
2012-2013 PLEASE NOTE:

These numbers are not comparable to those published in previous years as of 2011, NIH calculating estimates using different data source:

2012 – NIH is using a different data source:

2012-2013 Medical Expenditure Panel Survey (MEPS) of the Agency for Healthcare Research and Quality

2012-2013 MEPS estimates based on more current, nationally representative data used extensively in scientific publications

2012-2013 direct and indirect costs will no longer be projected to current year, estimates of indirect morbidity costs discontinued

2012-2013 For more information, please visit nhlbi.nih.gov/about/factpdf.htm.
——————————————————————
Lack of health insurance and other barriers prevents many Americans from receiving optimal health care
——————————————————————
2008 – early release estimates from National Health Interview Survey (2009)
2006 – early release estimates from the National Health Interview Survey (2008)
2004National Health Interview Survey data (2007)
2003National Health Interview Survey data (2006)
——————————————————————
2008 – about 24% aged 18 to 64 years (2009)
2006☝about 24% aged 18-64 (2008)
2004 – about 17% younger than age 65 had no health insurance coverage (2007)
2003☝about 17% younger than age 65 have no health insurance coverage (2006)
——————————————————————
2004 – 27% 65 and older had Medicare coverage only (2007)
2003☝24% 65 and older have Medicare coverage only (2006)
——————————————————————
2008 – 13% of children had no health insurance coverage for at least part of past year (2009)
2006☝13% of children had no health insurance coverage for at least part of past year (2008)
——————————————————————
2008 – More than 36% of adults who lack high school diploma were uninsured in past year (2009)
2006☝Almost 34% of adults who lack high school diploma were uninsured in past year (2008)
——————————————————————
2008 – 23% of high school graduates (2009)
2006☝23% of high school graduates (2008)
——————————————————————
2008👇14% of those with more than high school education (2009)
2006 – 15% of those with more than high school education (2008)
——————————————————————
2008 – Lack of health insurance is not only a concern of unemployed; almost one-quarter of employed individuals (aged 18 to 64 years) were uninsured sometime during past year (2009)
——————————————————————
2004 – Persons in lowest income group 10 times as likely as persons in highest income group not to receive needed medical care because of cost (2007)
——————————————————————
2004 – Almost 16 million citizens (6%) were unable to obtain needed medical care due to cost (2007)
——————————————————————
2003 – In survey, nearly 20% aged 18-44 years reported not having usual place to go for medical care (2006)
——————————————————————
2010-2013 – Uninsured patients and ethnic minorities substantially more likely to be diagnosed with cancer at later stage, when treatment can be more extensive and more costly
——————————————————————
2012-2013 – For more information on relationship between health insurance and cancer, see Cancer Facts & Figures 2008, Special Section, available online at cancer.org/statistics.
2010 – cancer.org.
2009 – (5008.08), Special Section, available online at cancer.org.
2008 – see special section page 22

20131122-005657.jpg

20131122-005720.jpg

20131122-005738.jpg

20131122-005752.jpg
======================================
REFERENCES:
======================================
2013:
——————————————————————
http://cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
======================================
2012:
——————————————————————
http://cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf
======================================
2011:
——————————————————————
http://cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf
======================================
2010:
——————————————————————
http://cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf
======================================
2009:
——————————————————————
http://cancer.org/acs/groups/content/@nho/documents/document/500809webpdf.pdf
======================================
2008:
——————————————————————
http://www.oralcancerfoundation.org/facts/pdf/worldcancer.pdf
=====================================
2007:
——————————————————————
http://cancer.org/acs/groups/content/@nho/documents/document/caff2007pwsecuredpdf.pdf
======================================
2006:
——————————————————————
http://cancer.org/acs/groups/content/@nho/documents/document/caff2006pwsecuredpdf.pdf
======================================
2005:
——————————————————————
http://cancer.org/acs/groups/content/@nho/documents/document/caff2005f4pwsecuredpdf.pdf
======================================
2004:
——————————————————————
http://www.pink-ribbon-pins.com/CancerRates2004.pdf
======================================
2003:
——————————————————————
http://www.whyquit.com/studies/2003_ACS_Cancer_Facts.pdf
======================================
2002:
——————————————————————
http://www.uhmsi.com/docs/CancerFacts&Figures2002.pdf
======================================

Critiquing: Doctor accused of selling false hope to families (USA TODAY NEWS, NATION, Liz Szabo, USA TODAY)

20131116-002847.jpg
I gave Liz Szabo and USA TODAY the chance to act like a Spike Lee joint and “Do the Right Thing”, the same day their article came out [1]

I gave them the opportunity to prove that their article was a legitimate piece of journalism with some semblance of integrity, and NOT just akin to one of “The Skeptics™ phoned-in “rubber-stamped” yellow journalism hit pieces

Instead, it seems that Liz Szabo and / or USA TODAY decided to act as if they had rolled a Spike Lee joint

I sent an e-mail with 2 editorial corrections, and only one (correcting Lisa Merritt’s comment
link from taking the reader to the 1999 Mayo Clinic report instead of to her comments), was corrected [2]

The 2nd correction which they #FAILED to do, earns them well deserved INSOLENCE
——————————————————————
The article claims:
——————————————————————
Burzynski, 70, calls his drugs “antineoplastons” and says he has given them to more than 8,000 patients since 1977.”
——————————————————————

20131116-004037.jpg
——————————————————————
However, if you select the “8,000 patients” link, the referenced page does NOT indicate that at all [2]
——————————————————————

20131116-064344.jpg
——————————————————————
It advises:
——————————————————————
“That same year, Dr. Burzynski founded his clinic in Houston where he’s since treated over 8,000 patients.” [3]
——————————————————————

20131116-064326.jpg
——————————————————————
Nowhere does it indicate that he “treated 8,000 patients” with antineoplastons
——————————————————————

20131116-064409.jpg
——————————————————————
The question that Liz Szabo and USA TODAY should answer, is:

1. Who is your “fact-checker”, and
2. are they smarter than a 5th grader ?
——————————————————————
In fact, Burzynski’s 2002 Securities and Exchange Commission (SEC) filing advises:

” … in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene targeted therapy, immunotherapy and hormonal therapy in response to FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston clinical trials” [4]
——————————————————————
The article continues:
——————————————————————
“Individual success stories can be misleading, said Arthur Caplan, a professor and head of the division of bioethics at NYU Langone Medical Center”
——————————————————————
The question Arthur Caplan should be asking is:

Why has the United States Food and Drug Administration required Burzynski’s clinical trial patients to fail conventional therapies; such as surgery, chemotherapy, and radiation, BEFORE they are allowed to be treated with antineoplaston therapy ?

If the F.D.A. did NOT impose these restrictions upon Burzynski’s clinical trials, then the question Arthur Caplan raises would be moot
——————————————————————
The article quotes Dr. Jan Buckner as saying:
——————————————————————
“When I hear a story that is way out of the norm, the first question I ask is,

‘OK, is the diagnosis even correct?‘ ”

Buckner said”

“If the diagnosis wasn’t right to start with, it doesn’t matter what the treatment was.”

“Brain tumors are notoriously difficult to diagnose, Buckner says”

“When dealing with rare brain cancer, doctors may disagree about how to interpret imaging results up to 40% of the time”
——————————————————————
I wonder if Dr. Jan Buckner would agree with David Gorski; who is a BREAST cancer oncology specialist, and NOT a BRAIN cancer oncology specialist, who has the presumptiveness to speculate that 3 different medical opinions could have misdiagnosed Tori Moreno in August 1998; who was diagnosed with a very large tumor, about 3 inches in the largest diameter and located in the brain stem, which was too risky for surgery, and about which her parents were told by ALL 3, that Tori’s brain cancer was fatal and, she would die in a few days or at the most, 2-6 weeks, and that there was nothing that could be done, and was finally put on Burzynski’s antineoplaston therapy in October, when she was about 3 ½ months old, and in such condition that they were afraid that she might die at any time, David H. Gorski, M.D., Ph.D., FACS; who claims, “I do know cancer science” , has the audacity, because of his “book learnin'” has the temerity to postulate his “science-based medicine theory” that Miller’s Children at Long Beach Memorial misdiagnosed Tori Moreno’s inoperable stage 4 BSG

David Gorski has the gall to profer that City of Hope misdiagnosed Tori Moreno’s inoperable stage 4 brain stem glioma

David Gorski has the chutzpah to pontificate that Dr. Fred Epstein in New York misdiagnosed Tori Moreno’s inoperable stage IV brainstem glioma [5]
——————————————————————
The article then quotes Peter Adamson, chair of the Children’s Oncology Group:
——————————————————————
“But these therapies may have delayed benefits, taking weeks or months to shrink a tumor

“So patients treated by Burzynski may credit him for their progress, just because he was the last doctor to treat them, says Peter Adamson, chair of the Children’s Oncology Group, an NCI-supported research network that conducts clinical trials in pediatric cancer

Conventional cancer treatment can also cause tumors to swell temporarily, due to inflammation

“A patient who isn’t familiar with this phenomenon may assume her tumor is growing

“When that swelling subsides, patients may assume it’s because of Burzynski, Adamson says”
——————————————————————
This is laughable

In support of this “phenomenon” , the article provides a link to a Canadian web-site [6]

The site posits:
——————————————————————
“RT/TMZ is now widely practiced and the standard of care for appropriately selected patients, we are learning more about the consequences of RT/TMZ”

“One phenomena, termed Pseudo-Progression (psPD)…”
——————————————————————
The problem is that this only applies to “Glioblastoma Multiforme (GBM)”, and the article provides NO proof whatsoever, that any of Burzynski’s “Glioblastoma Multiforme (GBM)” patients have taken “RT/TMZ”
——————————————————————
Additionally, the site cites the reference as:

Sanghera, Perry, Sahgal, et al., “Sunnybrook Health Sciences Odette Cancer Centre” (in press, Canadian Journal of Neuroscience)

(“In press” refers to journal articles which have been accepted for publication, but have not yet been published)

However, the journal article in question was published 1/2010, so it has NOT been “in press” for over 3 years and 7 months [7]

Get your act together, aye, Canada !
——————————————————————
The article rants and raves on and on about FDA inspection reports from as far back as 1998, but at least they did quote Richard A. Jaffe:

“In Burzynski’s defense, Jaffe notes that inspection reports represent preliminary findings

“The FDA has not yet issued final conclusions”
——————————————————————
The article posts this ridiculous claim:
——————————————————————
“Yet the National Cancer Institute says there is no evidence that Burzynski has cured a single patient, or even helped one live longer
——————————————————————
That’s NOT what this seems to suggest [8]
——————————————————————
Then the article quotes pediatric oncologist Peter Adamson, a professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia, in what will no doubt soon be known as a “classic”:
——————————————————————
“He’s a snake oil salesman,” says pediatric oncologist Peter Adamson, a professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia”
——————————————————————
All I’d like to know is, which rock did this clown crawl out from under ?

Dr. Adamson, please advise which “snake oil” has been granted Orphan Drug Designation (“ODD”) from the United States Food and Drug Administration [9], and which “snake oil” has been approved for, and used in, phase III clinical trials ? [10]
——————————————————————
Q: Is it, it the phase 2 trial is finished ?

A: “Mhmm”

Q: but they’re still accepting people ?

A: “Yeah”

Q: on more like a special ?

A: Special basis, and, um, sometimes compassionate grounds

A: “(compassion exception)”

A: “Uh, exceptions

Q: That’s normal ?

A: “Yes”
“So”

A: “(Yes I guess it is a funding issue ?)”

Q: Right

A: “(Like FDA, during the 2nd phase of clinical trials they found the data to be, real, real one, and they gave him the ok to go for 3rd phase of clinical trials, but just to go through this process you would probably need $100,000)”
——————————————————————

20131116-164617.jpg

20131021-200529.jpg

20131021-200553.jpg
——————————————————————
Oh, wait !!

Dr. Adamson, when you say “snake oil”, I take it you are referring to the low-dose chemotherapy that Burzynski uses ?

Dr. Adamson, do you know what a “hack” is ?
——————————————————————
In regards to the Merritt’s, the article has:
——————————————————————
“The couple say that Burzynski misled them about the type of treatment that would be offered, as well as the cost”

My questions about the Merritt’s are:

1. Where is their complaint to the Texas Medical Board ?

2. Where is their lawsuit ? Couldn’t they find an attorney to take their case pro bono ?
——————————————————————
The article continues:
——————————————————————
“Yet even Jaffe has acknowledged that the trialnow in its 17th year — was more about politics than science”

“In his 2008 memoirs, Galileo’s Lawyer, Jaffe called it “a joke.”

“”It was all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment,” Jaffe said
——————————————————————
What Liz Szabo and her friends at USA TODAY fail to let the readers know, is that this only applied to one trial:
——————————————————————
Burzynski’s lawyer is obviously referring to the CAN-1 clinical trial mentioned in Burzynski’s 11/25/1997 Securities and Exchange Commission (SEC) filing [11]
——————————————————————
One trial that is retrospective is CAN-1 Clinical Trial
——————————————————————
CAN-1 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH REFRACTORY MALIGNANCIES

133 patients
——————————————————————
Clinical trial of patients treated by Dr. Burzynski through 2/23/1996
——————————————————————
FDA has indicated it will not accept data generated by this trial since it was not a wholly prospective one
——————————————————————
The article continues in the same vein:
——————————————————————
“In an interview, Burzynski said developing new drugs is complex and takes time

“Yet the FDA has approved 108 cancer drugs since Burzynski began his trial”
——————————————————————
Ms. Szabo and “pals” conveniently “forgets” to educate their audience that Burzynski was using Fleming’s One-sample multiple testing procedure for phase II clinical trials [13], which requires that if the 1st 20 patients meet certain criteria, 20 additional patients are added [14]
——————————————————————
“Well, we cannot publish until the time is right” (laughs)

Yeah

“If you would like to publish the results of, of a
10 year survival, for instance”

Mmm

“Which we have
Nobody has over 10 year survival in
malignant brain tumor, but we do, and if you like to do it right, it takes time to prepare it, and that’s what we do now
What we publish so far
We publish numerous, uh, publications which were, interim reports when we are still continuing clinical trials
Now we are preparing, a number of publications for final reports
[15]
——————————————————————
Then Fran Visco, president of the National Breast Cancer Coalition makes an outlandish statement, which is quoted in the article:
——————————————————————
“Fran Visco, president of the National Breast Cancer Coalition, describes the FDA’s tolerance of Burzynski as “outrageous.”

“They have put people at risk for a long time,” says Visco, an attorney and breast cancer survivor

“That’s completely unacceptable”

“How can anyone look at these facts and believe that there is a real clinical trial going on … rather than just using the FDA and the clinical trial system to make money?”
——————————————————————
I have a suggestion for Ms. Visco

Take your hypocrisy and ask the American Cancer Society if they are still engaged in this kind of activity:

1. AMERICAN CANCER SOCIETY: More Interested In Accumulating Wealth Than Saving Lives [15]

2. National Cancer Institute and American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest [16]
——————————————————————
Then, ask the American Cancer Society, why is it that 10 years ago, estimated breast cancer deaths were expected to be 39,800 (15%), and this year it was 39,620 (14%), which is ONLY 180 LESS than 10 years ago ?
——————————————————————
Estimated Breast Cancer Deaths (Women)-USA
——————————————————————
2013☝39,620 (14%)
2012👇39,510 (14%)
2011👇39,520 (15%)
2010👇39,840 (15%)
2009👇40,170 (15%)
2008☝40,480 (15%)
2007👇40,460 (15%)
2006☝40,970 (15%)
2005👇40,410 (15%)
2004☝40,110 (15%)
2003☝39,800 (15%)
2002
39,600 (15%)
—————————————————————–
American Cancer Society Cancer Facts & Figures (2002-2013)
—————————————————————–
And then ask the American Cancer Society, why is it that 10 years ago, the estimated NEW breast cancer cases were expected to be 211,300 (32%), and this year it was 232,340 (29%), which is 21,340 MORE than it was 10 years ago ?
——————————————————————
Estimated New Breast Cancer (Women) – USA
——————————————————————
2013☝232,340 (29%)
2012👇226,870 (29%)
2011☝238,480 (30%)
2010☝207,090 (28%)
2009☝192,370 (27%)
2008☝182,460 (26%)

2007👇178,480 (26%)
2006☝212,920 (31%)
2005👇211,240 (32%)
2004☝215,900 (32%)
2003☝211,300 (32%)
2002
_-_203,500 (31%)
—————————————————————–
American Cancer Society Cancer Facts & Figures (2002-2013)
——————————————————————
And after that, ask Susan G. Komen how much is spent on legal action to protect her brand, compared to how much is spent on breast cancer research and prevention ?
——————————————————————
Visco, the breast cancer advocate

“I do NOT know why it took YOU so long.”
——————————————————————
The article continues with:
——————————————————————
“Yet hypernatremia is one of antineoplastons’ most common side effects, known to doctors for two decades”
——————————————————————
Yet, “The Skeptics™” refuse to discuss:
——————————————————————
2/13/2013 – The frequency, cost, and clinical outcomes of hypernatremia in patients hospitalized to a comprehensive cancer center

Over 3 month period in 2006 re 3,446 patients, most of the hypernatremia (90 %) was acquired during hospital stay [19]

Division of Internal Medicine, UT MD Anderson Cancer Center, Houston, TX, USA

Department of General Internal Medicine, University of Texas MD Anderson Cancer Center

Division of Endocrinology, Mayo Clinic
——————————————————————
9/1999 – The changing pattern of hypernatremia in hospitalized children [20]

Department of Pediatrics, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas, USA
——————————————————————
So, after all that, my question for USA TODAY is, does Liz Szabo, Michael Stravato, Jerry Mosemak or Robert Hanashiro have a
journalism degree ?

Because if any of them do, the institution they obtained it from most be so proud of this piece of “fish wrap” you produced

Thank you, USA TODAY, for censoring my 18 comments

I guess you must be (“intellectual”) cowards

At least Forbes had the GRAPEFRUITS to post some of my comments
——————————————————————
You’ve just been served, INSOLENTLY
——————————————————————
USA TODAY, GONE TOMORROW
——————————————————————

20131116-084820.jpg

20131116-085357.jpg

20131116-084833.jpg

20131116-084847.jpg

20131116-084909.jpg

20131116-084924.jpg

20131116-084937.jpg

20131116-085152.jpg

20131116-085218.jpg

20131116-085311.jpg

20131116-085436.jpg

20131116-085528.jpg

20131116-085550.jpg

20131116-085608.jpg

20131116-085629.jpg

20131116-084804.jpg

20131116-084745.jpg
======================================
REFERENCES:
======================================
[1] – 11/15/2013 – USA TODAY NEWS, NATION
Doctor accused of selling false hope to families
Liz Szabo, USA TODAY
——————————————————————
http://www.usatoday.com/story/news/nation/2013/11/15/stanislaw-burzynski-cancer-controversy/2994561/
======================================
[2] – Mayo Clinic – 1999 – report: Lisa Merritt
——————————————————————
https://www.documentcloud.org/documents/816819-mayo-clinic-1999-report.html
======================================
[3] – 2012 – former Burzynski web-site screenshots, Pg 3 of 62;
——————————————————————
http://www.circare.org/info/bri/burzynski_fdauntitled_promo_2012.pdf
======================================
[4] – 4/26/2013 – Burzynski: FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston CLINICAL TRIALS:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/26/burzynski-fda-requirements-that-cancer-patients-utilize-more-traditional-cancer-treatment-options-in-order-to-be-eligible-to-participate-in-the-companys-antineoplaston-clinical-trials/
======================================
[5] – 11/14/2013 – Critiquing: Why we fight for patients (Why we fight your patience) TAM 2013, TAM2013, “The Amazing Meeting” 2013 #TAM2013 http://www.theamazingmeeting.com
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/14/tam-2013-tam2013-tam2013-the-amazing-meeting-2013-the-amazing-meeting-httptheamazingmeeting-com-httpwww-theamazingmeeting-com/
======================================
[6] – Phenomenon – Brain Tumour Foundation of Canada
——————————————————————
http://www.braintumour.ca/1649/ask-the-expert-psuedo-progression-gbm
======================================
[7] – Pseudoprogression following chemoradiotherapy for glioblastoma multiforme
Can J Neurol Sci. 2010 Jan;37(1):36-42
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/20169771/
======================================
[8] – 9/19/2013 – Critiquing: National Cancer Institute (NCI) at the National Institutes of Health (NIH) CancerNet “fact sheet” :
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/19/critiquing-national-cancer-institute-nci-at-the-national-institutes-of-health-nih-cancernet/
======================================
[9] – FDA Orphan Drug Designation
——————————————————————
http://www.burzynskiresearch.com/assets/PressRelease_12022008_BZYR(2).pdf
======================================
[10] – 11/7/2013Pete Cohen chats with Sonali Patil, Ph.D., Research Scientist at The Burzynski Clinic:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/07/pete-cohen-chats-with-sonali-patil-ph-d-research-scientist-at-the-burzynski-clinic/
======================================
[11] – 7/9/2013 – Burzynski: The Original 72 Phase II Clinical Trials:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/09/burzynski-the-original-72-phase-ii-clinical-trials/
======================================
[12] – 8/21/2013 – Critiquing David H. Gorski, MD, PhD, FACS http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/21/critiquing-david-h-gorski-md-phd-facs-www-sciencebasedmedicine-orgeditorial-staffdavid-h-gorski-md-phd-managing-editor/
======================================
[13] – 2003 – pg. 94
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf
======================================
[14] – 3/1982 – Biometrics 1982; 38: 143-51
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/7082756/
======================================
[15] – 11/9/2013Pete Cohen chats with Dr. Stanislaw Burzynski – Interview #2:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/09/pete-cohen-chats-with-dr-stanislaw-burzynski-interwiew-2/
======================================
[16] – AMERICAN CANCER SOCIETY: More Interested In Accumulating Wealth Than Saving Lives
——————————————————————
http://www.wnho.net/acs.pdf
======================================
[17] – 9/11/2013 – National Cancer Institute and American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/11/national-cancer-institute-and-american-cancer-society-criminal-indifference-to-cancer-prevention-and-conflicts-of-interest/
—————————————————————
[18] – 11/13/2013 – The War on Cancer (I don’t think it means, what you think it says it means) #Winning?
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/13/httpcancer-orgacsgroupscontentepidemiologysurveilancedocumentsdocumentacspc-036845-pdf/
======================================
[19] – 4/24/2013 – Burzynski: HYPERNATREMIA:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/24/burzynski-hypernatremia/
======================================
[20] – 9/1999 – Pediatrics. 1999 Sep;104(3 Pt 1):435-9
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/10469766/
======================================

20131116-002912.jpg

The War on Cancer (I don’t think it means, what you think it says it means) #Winning?

“In 1971, the ACS (American Cancer Society) aggressively campaigned President Nixon to declare the “War on Cancer,” claiming that this could be won, given increased funding for the National Cancer Institute (NCI)

“President Nixon responded by increasing its funding by $200,000”

“This was in excess of the funding that it then received as one of 30 other National Institutes of Health”

“In so doing, President Nixon effectively created an independent status for the NCI [0]
——————————————————————
American Cancer Society
——————————————————————
Cancer Facts & Figures 2002-2013
——————————————————————
Expected New Cancer Cases – USA
——————————————————————
2013☝1,660,290 – (21,380 more than 2012)
2012☝1,638,910 – (42,240 more than 2011)
2011☝1,596,670 – (67,160 more than 2010)
2010☝1,529,560 – (49,810 more than 2009)
2009☝1,479,350 – (42,170 more than 2008)

2008👇1,437,180 – ( 7,740 less than 2007)
2007☝1,444,920 – (45,130 more than 2006)
2006☝1,399,790 – (26,880 more than 2005)
2005☝1,372,910 – ( 4,870 more than 2004)
2004☝1,368,030 – (33,930 more than 2003)
2003☝1,334,100 – (49,200 more than 2002)
2002
1,284,900
——————————————————————
Expected to Die – United States
——————————————————————
2013☝580,350_-_(3,160 more than 2012)
2012☝577,190
_-_(5,240 more than 2011)
2011☝571,950
_-_(2,460 more than 2010)
2010☝569,490
_-_(7,150 more than 2009)
2009👇562,340_-_(3,310 less than 2008)
2008☝565,650_-_(6,000 more than 2007)
2007👇559,650_-_(5,180 less than 2006)
2006👇564,830_-_(5,450 less than 2005)
2005☝570,280_-_(6,580 more than 2004
2004☝563,700
_-_(7,200 more than 2003)
2003☝556,500
_-_(6,000 more than 2002)
2002
_-_555,500
——————————————————————
Deaths – United States of America
——————————————————————
2013almost 1,600 a day
2012 – 1,500+ a day
2011 – 1,500+ a day
2010 – 1,500+ a day
2009 – 1,500+ a day
2008 – 1,500+ a day
2007 – 1,500+ a day
2006 – 1,500+ a day
2005 – 1,500+ a day
2004 – 1,500+ a day
2003 – 1,500+ a day
======================================
Estimated Childhood Cancer Deaths (0-14 years)
——————————————————————
2013👇1, 310
2012☝1,340
2011👇1,320
2010👇1,340
2009👇1,380
2008👇1,490
2007👇1,545
2006👇1,560
2005☝1,585
2004☝1,510
2003☝1,500
2002
1,400
——————————————————————
Estimated New Childhood Cancer (0-14 years)
——————————————————————
2013👇11,630
2012☝12,060
2011☝11,210

2010👇10,700
200910,730
2008☝10,730
2007☝10,400

2006👇9,500
2005☝9,510
2004☝9,200

2003👇9,000
20029,100
======================================
Estimated Brain and other nervous system Cancer Deaths (Women)
——————————————————————
2013☝6,150 (2%)
2012☝5,980 (2%)

2011👇5,670 (2%)
2010☝5,720 (2%)
2009👇5,590 (2%)
2008☝5,650 (2%)
2007☝5,590 (2%)
2006☝5,560 (2%)

2005👇5,480 (2%)
2004👇5,490 (2%)
2003👇5,800 (2%)
20025,900 (2%)
======================================
Estimated All Cancer Deaths (Women)
——————————————————————
2013👇273,430 (100%)
2012☝275,370 (100%)
2011☝271,520 (100%)
2010☝270,290 (100%)

2009👇269800 (100%)
2008☝271,530 (100%)
2007👇270,100 (100%)
2006👇273,560 (100%)
2005☝275,000 (100%)
2004☝272,810 (100%)
2003☝270,600 (100%)
2002
_-_267,300 (100%)
——————————————————————
Estimated Lung and bronchus Cancer Deaths (Women)
——————————————————————
2013👇72,220 (26%)
2012☝72,590 (26%)
2011☝71,340 (26%)
2010☝71,080 (26%)

2009👇70,490 (26%)
2008☝71,030 (26%)
2007👇70,880 (26%)
2006👇72,130 (26%)
2005☝73,020 (27%)
2004👇68,510 (25%)
2003☝68,800 (25%)
2002
65,700 (25%)
——————————————————————
Estimated Breast Cancer Deaths (Women)
——————————————————————
2013☝39,620 (14%)
2012👇39,510 (14%)
2011👇39,520 (15%)
2010👇39,840 (15%)
2009👇40,170 (15%)
2008☝40,480 (15%)
2007👇40,460 (15%)
2006☝40,970 (15%)
2005👇40,410 (15%)
2004☝40,110 (15%)
2003☝39,800 (15%)
2002
39,600 (15%)
——————————————————————
Estimated Colon and rectum Cancer Deaths (Women)
——————————————————————
2013👇24,530 (9%)
2012☝25,220 (9%)
2011👇24,130 (9%)
2010👇24,790 (9%)
2009👇24,680 (9%)
2008👇25,790 (9%)
2007👇26,180 (10%)
2006👇27,300 (10%)
2005👇27,750 (10%)
2004👇28,410 (10%)
200328,800 (11%)
2002
28,800 (11%)
——————————————————————
Estimated Pancreas Cancer Deaths (Women)
——————————————————————
2013☝18,970 (7%)
2012☝18,540 (7%)
2011☝18,300 (7%)
2010☝18,030 (7%)
2009☝17,210 (6%)
2008☝16,790 (6%)
2007☝16,530 (6%)
2006☝16,210 (6%)
2005☝15,980 (6%)
2004☝15,830 (6%)
2003☝15,300 (16%)
2002
15,200 (16%)
——————————————————————
Estimated Ovary Cancer Deaths (Women)
——————————————————————
2013👇14,030 (5%)
2012☝15,500 (6%)
2011☝15,460 (6%)

2010👇13,850 (5%)
2009👇14,600 (5%)
2008☝15,520 (6%)
2007👇15,280 (6%)
2006👇15,310 (6%)
2005☝16,210 (6%)
2004☝16,090 (6%)
2003☝14,300 (5%)
2002
13,900 (5%)
——————————————————————
Estimated Leukemia Deaths (Women)
——————————————————————
2013☝10,060 (4%)
2012☝10,040 (4%)

2011👇9,040 (3%)
2010👇9,180 (3%)
2009☝9,280 (3%)
2008👇9,250 (3%)
2007👇9,470 (4%)
2006👇9,810 (4%)
2005👇10,030 (4%)
2004☝10,310 (4%)
2003☝9,800 (4%)
2002
9,600 (4%)
——————————————————————
Estimated Non-Hodgkin lymphoma Deaths (Women)
——————————————————————
2013👇8,430 (3%)
2012👇8,620 (3%)
2011☝9,570 (4%)
2010👇9,500 (4%)
2009☝9,670 (4%)
2008☝9,370 (3%)
2007☝9,060 (3%)

2006👇8,840 (3%)
2005☝9,050 (3%)
2004👇9,020 (3%)
2003👇11,200 (4%)
200211,700 (4%)
——————————————————————
Estimated Uterine corpus Cancer Deaths (Women)
——————————————————————
2013☝8,190 (3%)
2012👇8,010 (3%)
2011☝8,120 (3%)
2010☝7,950 (3%)
2009☝7,780 (3%)
2008☝7,470 (3%)
2007☝7,400 (3%)
2006☝7,350 (3%)
2005☝7,310 (3%)
2004☝7,090 (3%)
2003☝6,800 (3%)
2002
6,600 (2%)
——————————————————————
Estimated Liver and intrahepatic bile duct Cancer Deaths (Women)
——————————————————————
2013☝6,780 (2%)
2012☝6,570 (2%)
2011☝6,330 (2%)
2010☝6,190 (2%)
2009☝6,070 (2%)
2008☝5,840 (2%)
2007
5,500 (2%)
2006
2005
2004
2003
2002
——————————————————————
Estimated Multiple myeloma Cancer Deaths (Women)
——————————————————————
2013
2012
2011
2010
2009
2008
2007
2006👇5,630 (2%)
20055,640 (2%)
2004☝5,640 (2%)
2003☝5,500 (2%)
2002
5,300 (2%)
======================================
Estimated New Cancer All (Women)
——————————————————————
2013☝805,500 (100%)
2012☝790,740 (100%)
2011☝774,370 (100%)
2010☝739,940 (100%)
2009☝713,220 (100%)
2008☝692,000 (100%)

2007👇678,060 (100%)
2006☝679,510 (100%)
2005👇662,870 (100%)
2004☝668,470 (100%)
2003☝658,800 (100%)
2002
_-_647,400 (100%)
——————————————————————
Estimated New Breast Cancer (Women)
——————————————————————
2013☝232,340 (29%)
2012👇226,870 (29%)
2011☝238,480 (30%)
2010☝207,090 (28%)
2009☝192,370 (27%)
2008☝182,460 (26%)

2007👇178,480 (26%)
2006☝212,920 (31%)
2005👇211,240 (32%)
2004☝215,900 (32%)
2003☝211,300 (32%)
2002
_-_203,500 (31%)
——————————————————————
Estimated New Lung and bronchus Cancer (Women)
——————————————————————
2013☝110,110 (14%)
2012☝109,690 (14%)
2011☝106,070 (14%)
2010☝105,770 (14%)
2009☝103,350 (14%)
2008☝100,330 (14%)
2007☝98,620 (15%)
2006☝81,770 (12%)

2005👇79,560 (12%)
2004☝80,660 (12%)
2003☝80,100 (12%)
2002
79,200 (12%)
——————————————————————
Estimated New Colon and rectum Cancer (Women)
——————————————————————
2013👇69,140 (9%)
2012☝70,040 (9%)
2011👇69,360 (9%)
2010👇70,480 (10%)
2009👇71,380 (10%)
2008👇71,560 (10%)
2007👇74,630 (11%)
2006☝75,810 (11%)
2005☝73,470 (11%)

2004👇73,320 (11%)
2003👇74,700 (11%)
200275,700 (12%)
——————————————————————
Estimated New Uterine corpus Cancer (Women)
——————————————————————
2013☝49,560 (6%)
2012☝47,130 (6%)
2011☝46,470 (6%)
2010☝43,470 (6%)
2009☝42,160 (6%)
2008☝41,100 (6%)

2007👇39,080 (6%)
2006☝41,200 (6%)
2005☝40,880 (6%)

2004👇40,320 (6%)
2003☝41,00 (6%)
2002
39,300 (6%)
——————————————————————
Estimated New Thyroid Cancer (Women)
——————————————————————
2013☝45,310 (6%)
2012☝43,210 (5%)
2011☝36,550 (5%)
2010☝33,930 (5%)

2009👇27,200 (4%)
2008☝28,410 (4%)
2007☝25,480 (4%)
2006☝22,590 (3%)
2005☝19,190 (3%)
2004☝17,640 (3%)
2003☝16,300 (3%)
2002
15,800 (2%)
——————————————————————
Estimated New Non-Hodgkin lymphoma (Women)
——————————————————————
2013☝32,140 (4%)
2012☝31,970 (4%)
2011☝30,300 (4%)
2010☝30,160 (4%)

2009👇29,990 (4%)
2008☝30,660 (4%)
2007☝28,990 (4%)
2006☝28,190 (4%)
2005☝27,320 (4%)
2004☝25,520 (4%)

2003👇25,100 (4%)
200225,700 (4%)
——————————————————————
Estimated New Melanoma of the skin Cancer (Women)
——————————————————————
2013👇31,630 (4%)
2012☝32,000 (4%)
2011☝30,220 (4%)

2010👇29,260 (4%)
2009☝29,640 (4%)
2008☝27,530 (4%)

2007👇26,030 (4%)
2006☝27,930 (4%)
2005☝26,000 (4%)
2004☝25,200 (4%)
2003☝24,300 (3%)
2002
23,500 (4%)
——————————————————————
Estimated New Kidney and renal pelvis Cancer (Women)
——————————————————————
2013☝24,720 (3%)
2012☝24,520 (4%)
2011☝23,800 (3%)
2010☝22,870 (3%)
2009☝22,330 (3%)
2008☝21,260 (3%)
2007
19,600 (3%)
2006
2005
2004
2003
2002
——————————————————————
Estimated New Pancreas Cancer (Women)
——————————————————————
2013☝22,489 (3%)
2012👇21,830 (3%)
2011☝21,980 (3%)
2010☝21,770 (3%)
2009 21,420 (3%)

2008
2007
2006☝16,580 (2%)
2005👇16,080 (2%)
2004☝16,120 (2%)
2003☝15,800 (2%)
2002
15,600 (2%)
——————————————————————
Estimated New Ovary Cancer (Women)
——————————————————————
2013👇22,240 (3%)
2012☝22,280 (3%)
2011☝21,990 (3%)
2010☝21,880 (3%)

2009👇21,550 (3%)
2008👇21,650 (3%)
2007☝22,430 (3%)
2006👇20,180 (3%)
2005👇22,220 (3%)
2004☝25,580 (4%)
2003☝25,400 (4%)
2002
23,300 (4%)
——————————————————————
Estimated New Leukemia (Women)
——————————————————————
2013
2012
2011
2010
2009
2008👇19,090 (3%)
200719,440 (3%)
2006
2005
2004
2003
2002
——————————————————————
Estimated New Urinary bladder Cancer (Women)
——————————————————————
2013
2012
2011
2010
2009
2008
2007
2006☝16,730 (2%)
2005☝16,200 (2%)
2004☝15,600 (2%)
2003
15,200 (2%)
2002
15,200 (2%)
======================================
Estimated All Cancer Deaths (Men)
——————————————————————
2013☝306,920 (100%)
2012☝301,820 (100%)
2011☝300,430 (100%)
2010☝299,200 (100%)

2009👇292,540 (100%)
2008☝294,120 (100%)
2007👇289,550 (100%)
2006👇291,270 (100%)
2005☝295,280 (100%)
2004☝290,890 (100%)

2003👇285,900 (100%)
2002_-_288,200 (100%)
——————————————————————
Estimated Lung and bronchus Deaths (Men)
——————————————————————
2013👇87,260 (28%)
2012☝87,750 (29%)
2011👇85,600 (28%)
2010👇86,220 (29%)
2009👇88,900 (30%)
2008☝98,810 (31%)
2007👇89,510 (31%)
2006👇90,330 (31%)
2005👇90,490 (31%)
2004☝91,930 (32%)
2003👇88,400 (31%)
200289,200 (31%)
——————————————————————
Estimated Prostate Cancer Deaths (Men)
——————————————————————
2013☝29,720 (10%)
2012👇28,170 (9%)
2011☝33,720 (11%)
2010☝32,050 (11%)

2009👇27,360 (9%)
2008☝28,660 (10%)
2007👇27,050 (9%)
2006👇27,350 (9%)
2005☝30,350 (10%)
2004☝29,500 (10%)

2003👇28,900 (10%)
200230,200 (11%)
——————————————————————
Estimated Colon and rectum Cancer Deaths (Men)
——————————————————————
2013👇26,300 (9%)
2012☝26,470 (9%)
2011👇25,250 (8%)
2010☝26,580 (9%)
2009☝25,240 (9%)

2008👇24,260 (8%)
2007👇26,000 (9%)
2006👇27,870 (10%)
2005☝28,540 (10%)
2004☝28,320 (10%)
2003☝28,300 (10%)
2002
27,800 (10%)
——————————————————————
Estimated Pancreas Cancer Deaths (Men)
——————————————————————
2013☝19,480 (6%)
2012👇18,850 (6%)
2011☝19,360 (3%)
2010☝18,770 (6%)
2009☝18,030 (6%)
2008☝17,500 (6%)
2007☝16,840 (6%)
2006☝16,090 (6%)
2005☝15,820 (5%)
2004☝15,440 (5%)
2003☝14,700 (5%)
2002
14,500 (5%)
——————————————————————
Estimated Liver and intrahepatic bile duct Cancer Deaths (Men)
——————————————————————
2013☝14,890 (5%)
2012☝13,980 (5%)
2011☝13,260 (4%)
2010☝12,720 (4%)

2009👇12,090 (4%)
2008☝12,570 (4%)
2007☝11,280 (4%)
2006☝10,840 (4%)
2005☝10,330 (3%)
2004☝9,450 (3%)
2003☝9,200 (3%)
2002
8,900 (3%)
——————————————————————
Estimated Leukemia Deaths (Men)
——————————————————————
2013☝13,660 (4%)
2012☝13,500 (4%)
2011☝12,740 (4%)
2010☝12,660 (4%)
2009☝12,590 (4%)
2008☝12,460 (4%)

2007👇12,320 (4%)
2006👇12,470 (4%)
2005👇12,540 (4%)
2004☝12,990 (5%)
2003
12,100 (4%)
2002
12,100 (4%)
——————————————————————
Estimated Esophagus Cancer Deaths (Men)
——————————————————————
2013☝12,220 (4%)
2012☝12,040 (4%)
2011☝11,910 (4%)
2010☝11,650 (4%)
2009☝11,490 (4%)
2008☝11,250 (4%)
2007☝10,900 (4%)
2006☝10,730 (4%)
2005☝10,530 (4%)
2004☝10,250 (4%)
2003☝9,900 (4%)
2002
9,600 (3%)
——————————————————————
Estimated Urinary bladder Cancer Deaths (Men)
——————————————————————
2013☝10,820 (4%)
2012👇10,510 (3%)
2011☝10,670 (4%)
2010☝10,410 (3%)
2009☝10,180 (3%)
2008☝9,950 (3%)
2007☝9,630 (3%)
2006☝8,990 (3%)
2005☝8,970 (3%)
2004☝8,780 (3%)
2003
8,600 (3%)
2002
8,600 (3%)
——————————————————————
Estimated Non-Hodgkin lymphoma Deaths (Men)
——————————————————————
2013☝10,590 (3%)
2012☝10,320 (3%)

2011👇9,750 (3%)
2010☝10,710 (4%)
2009☝9,830 (3%)
2008☝9,790 (3%)

2007👇9,600 (3%)
2006👇10,000 (3%)
2005👇10,150 (3%)
2004👇10,390 (4%)
2003👇12,200 (4%)
200212,700 (5%)
——————————————————————
Estimated Kidney and renal pelvis Cancer Deaths (Men)
——————————————————————
2013☝8,780 (3%)
2012☝8,650 (3%)
2011☝8,270 (3%)
2010☝8,210 (3%)
2009☝8,160 (3%)
2008☝8,100 (3%)

2007👇8,080 (3%)
2006☝8,130 (3%)
2005☝8,020 (3%)
2004☝7,870 (3%)
2003☝7,409 (3%)
2002
7,200 (3%)
======================================
Estimated New Cancer All (Men)
——————————————————————
2013☝854,790 (100%)
2012☝848,170 (100%)
2011☝822,300 (100%)
2010☝789,620 (100%)
2009☝766,130 (100%)

2008👇745,180 (100%)
2007☝766,860 (100%)
2006☝720,280 (100%)
2005☝710,040 (100%)
2004☝699,560 (100%)
2003☝675,300 (100%)
2002
_-_637,500 (100%)
——————————————————————
Estimated New Prostate Cancer (Men)
——————————————————————
2013👇238,590 (28%)
2012☝241,470 (29%)
2011☝240,890 (29%)
2010☝217,730 (28%)
2009☝192,280 (25%)

2008👇186,320 (25%)
2007👇218,890 (29%)
2006☝234,460 (33%)
2005☝232,090 (33%)
2004☝230,110 (33%)
2003☝220,900 (33%)
2002
_-_189,000 (30%)
——————————————————————
Estimated New Lung and bronchus Cancer (Men)
——————————————————————
2013☝118,080 (14%)
2012☝116,470 (14%)

2011👇115,060 (14%)
2010☝116,750 (15%)
2009☝116,090 (15%)

2008👇114,690 (15%)
2007☝114,760 (15%)
2006👇92,700 (13%)
2005👇93,010 (13%)
2004☝93,110 (13%)
2003☝91,800 (14%)
2002
90,200 (14%)
——————————————————————
Estimated New Colon and rectum Cancer (Men)
——————————————————————
2013☝73,680 (13%)
2012☝73,420 (9%)

2011👇71,850 (9%)
2010👇72,090 (9%)
2009👇75,590 (10%)
2008👇77,250 (10%)
2007☝79,130 (10%)
2006☝72,800 (10%)

2005👇71,820 (10%)
2004☝73,620 (11%)
2003☝72,800 (11%)
2002
72,600 (11%)
——————————————————————
Estimated New Urinary bladder Cancer (Men)
——————————————————————
2013👇54,610 (6%)
2012☝55,600 (7%)
2011👇52,020 (6%)
2010👇52,760 (7%)
2009☝52,810 (7%)
2008☝51,230 (7%)
2007☝50,040 (7%)

2006👇44,690 (6%)
2005☝47,010 (7%)
2004☝44,640 (6%)
2003☝42,200 (6%)
2002
41,500 (7%)
——————————————————————
Estimated New Melanoma of the skin Cancer (Men)
——————————————————————
2013☝45,060 (5%)
2012☝44,250 (5%)
2011☝40,010 (5%)

2010👇38,870 (5%)
2009☝39,080 (5%)
2008☝34,950 (5%)

2007👇33,910 (4%)
2006☝34,260 (5%)
2005☝33,580 (5%)
2004 – 29,900 (4%)

2003👇29,900 (4%)
200230,100 (5%)
——————————————————————
Estimated New Kidney and renal pelvis Cancer (Men)
——————————————————————
2013☝40,430 (5%)
2012☝40,250 (5%)
2011☝37,120 (5%)

2010👇35,370 (4%)
2009☝35,430 (5%)
2008☝33,130 (4%)
2007☝31,590 (4%)
2006☝24,650 (3%)
2005☝22,490 (3%)
2004☝22,080 (3%)
2003☝19,500 (3%)
2002
19,100 (3%)
——————————————————————
Estimated New Non-Hodgkin lymphoma (Men)
——————————————————————
2013👇37,600 (4%)
2012☝38,160 (4%)
2011☝36,060 (4%)

2010👇35,380 (4%)
2009☝35,990 (5%)
2008☝35,450 (5%)
2007☝34,200 (4%)
2006☝30,680 (4%)
2005☝29,070 (4%)
2004☝28,850 (4%)
2003☝28,300 (4%)
2002
28,200 (4%)
——————————————————————
Estimated New Oral cavity and pharynx Cancer (Men)
——————————————————————
2013☝29,620 (3%)
2012☝28,540 (3%)
2011☝27,710 (3%)
2010☝25,420 (3%)

2009👇25,240 (3%)
2008☝25,310 (3%)
2007☝24,180 (3%)
2006☝20,180 (3%)
2005☝19,100 (3%)
2004☝18,550 (3%)

2003👇18,200 (3%)
200218,900 (3%)
——————————————————————
Estimated New Leukemia (Men)
——————————————————————
2013☝27,880 (3%)
2012☝26,830 (3%)
2011☝25,320 (3%)

2010👇24,690 (3%)
2009☝25,630 (3%)
2008☝25,180 (3%)
2007☝24,800 (3%)
2006☝20,000 (3%)
2005☝19,640 (3%)
2004☝19,020 (3%)
2003☝17,900 (3%)
2002
17,600 (3%)
——————————————————————
Estimated New Pancreas Cancer (Men)
——————————————————————
2013☝22,740 (3%)
2012☝22,090 (3%)
2011☝22,050 (3%)
2010☝21,370 (3%)
2009☝21,050 (3%)

2008👇18,770 (3%)
2007☝18,830 (2%)
2006☝17,150 (2%)
2005☝16,109 (2%)
2004☝15,740 (2%)
2003☝14,900 (2%)
2002
14,700 (2%)
======================================

20131113-231037.jpg

20131113-113632.jpg
——————————————————————
American Cancer Society
——————————————————————
Cancer Facts & Figures
======================================
REFERENCES:
======================================
[0] – AMERICAN CANCER SOCIETY

More Interested In Accumulating Wealth Than Saving Lives

Samuel S. Epstein, M.D.

Emeritus professor Environmental and Occupational Medicine

University of Illinois School of Public Health

and

Chairman, The Cancer Prevention Coalition
——————————————————————
http://www.wnho.net/acs.pdf
======================================
2013
——————————————————————
http://cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
——————————————————————
http://m.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
======================================
2012
——————————————————————
http://cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf
——————————————————————
http://m.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/index
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012
======================================
2011
——————————————————————
http://cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf
——————————————————————
http://m.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011
======================================
2010
——————————————————————
http://cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf
——————————————————————
http://m.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index
======================================
2009
——————————————————————
http://cancer.org/acs/groups/content/@nho/documents/document/500809webpdf.pdf
——————————————————————
http://m.cancer.org/acs/groups/content/@nho/documents/document/500809webpdf.pdf
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2009
======================================
2008
——————————————————————
http://www.oralcancerfoundation.org/facts/pdf/worldcancer.pdf
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2008/index
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
======================================
2007
——————————————————————
http://cancer.org/acs/groups/content/@nho/documents/document/caff2007pwsecuredpdf.pdf
——————————————————————
http://m.cancer.org/acs/groups/content/@nho/documents/document/caff2007pwsecuredpdf.pdf
——————————————————————
http://cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2007
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2007
======================================
2006
——————————————————————
http://cancer.org/acs/groups/content/@nho/documents/document/caff2006pwsecuredpdf.pdf
——————————————————————
http://m.cancer.org/acs/groups/content/@nho/documents/document/caff2006pwsecuredpdf.pdf
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2006
======================================
2005
——————————————————————
http://cancer.org/acs/groups/content/@nho/documents/document/caff2005f4pwsecuredpdf.pdf
——————————————————————
http://m.cancer.org/acs/groups/content/@nho/documents/document/caff2005f4pwsecuredpdf.pdf
——————————————————————
http://cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://m.cancer.org/research/cancerfactsstatistics/allcancerfactsfigures/index
——————————————————————
http://cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005
——————————————————————
http://m.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2005
======================================
2004
——————————————————————
http://www.pink-ribbon-pins.com/CancerRates2004.pdf
======================================
2003
——————————————————————
http://www.whyquit.com/studies/2003_ACS_Cancer_Facts.pdf
======================================
2002
——————————————————————
http://www.uhmsi.com/docs/CancerFacts&Figures2002.pdf
======================================

National Cancer Institute and American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest

[1] – 1998 – According to Epstein, “Dr. Samuel Broder, National Cancer Institute (NCI) director from 1989 to 1995, frankly admitted, in a 1998 Washington Post interview:

‘the NCI has become what amounts to a government pharmaceutical company.’

“Taxpayers have funded R & D and expensive clinical trials for over two-thirds of cancer drugs on the market”

These drugs are given, with exclusive rights, to the industry, which sells them at inflated prices.”
====================================
REFERENCES:
====================================
[1] – 1998
——————————————————————
http://www.naturalnews.com/032700_National_Cancer_Institute_Dr_Samuel_Epstein.html
——————————————————————
http://m.naturalnews.com/news/032700_National_Cancer_Institute_Dr_Samuel_Epstein.html
====================================
[2] – 7/26/2000 – The Politics of Cancer, Vol. 284 No. 4, July 26, 2000, Samuel S. Epstein, MD, University of Illinois, Chicago
——————————————————————
http://jama.jamanetwork.com/Mobile/issue.aspx?journalid=67&issueid=4745&direction=P
——————————————————————
http://www.preventcancer.com/publications/pdf/letter_JAMA_july262000.htm
====================================
[3] – AMERICAN CANCER SOCIETY, More Interested In Accumulating Wealth Than Saving Lives (130 pgs.), Samuel S. Epstein, M.D., Emeritus professor, Environmental and Occupational Medicine University of Illinois School of Public Health and Chairman, The Cancer Prevention Coalition
AMERICAN CANCER SOCIETY DEBATES EPSTEIN, 19 Corporate Crime Reporter 20(1), May.10, 2005 (Pg. 129)

——————————————————————
http://www.wnho.net/acs.pdf
——————————————————————
http://www.karlloren.com/biopsy/p60.htm
====================================

Critiquing: American Cancer Society – Antineoplaston Therapy

[1] – The American Cancer Society Antineoplaston Therapy Overview claims:
=====================================
=====================================
” In other words, there is no convincing evidence showing that antineoplastons actually work
=====================================
=====================================
====================================
Interestingly, the above Overview does NOT provide any specific citation(s), reference(s), or link(s) to support this claim
——————————————————————
[2] – 10/4/1991 – Five doctors (3 from the Cancer Therapy Evaluation Branch (CTEP); including the Head of the Quality Assurance and Compliance Section, Regulatory Affairs Branch, Cancer Therapy Evaluation Program, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, and 2 invited consultants; including one from the National Institutes of Health (NIH) Clinical Center) visited the offices of Dr. Stanislaw R. Burzynski
——————————————————————
[3] – 10/31/1991 – Michael A. Friedman, M.D. Associate Director, Cancer Therapy Evaluation Program (CTEP), Department of Health &Human Services, National Institutes of Health, National Cancer Institute, sent a one page Memorandum to Bruce A. Chabner, M.D., Director, Division of Cancer Treatment, which stated, in part:

“I thought you would be interested in this for several reasons:”

“3. Antineoplastons deserve a closer look”

“It turns out that the agents are well defined, pure chemical entities
=======================================
=======================================
“The human brain tumor responses are real”

20130911-102213.jpg
=======================================
[4] – 11/15/1991 – Michael J. Hawkins, M.D., Chief, Investigational Drug Branch, Department of Health &Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, sent a 7 page letter to Decision Network, which stated, in part, on page one:
=======================================
=======================================
“It was the opinion of the site visit team that antitumor activity was documented in this best case series … “

20130911-122216.jpg
=======================================
[5] – 12/2/91 – NCI (National Cancer Institute), Decision Network Report on Antineoplastons, states in part, on page 11:
=======================================
=======================================
“The site visit team determined that antitumor activity was documented in this best case series … “

20130911-134634.jpg
=======================================
[6] – CANCER FACTS
National Cancer Institute • National Institutes of Health Department of Health and Human Services, Antineoplastons, pg. 1

=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “

20130911-094155.jpg
=======================================
[7] – Page 1 of 6, BlueCross BlueShield of Alabama, Antineoplaston Cancer Therapy, Policy #: 280, Category: Medicine, states, in part, on page 2 of 6:

Key Points:
=======================================
=======================================
“The reviewers of this series found evidence of antitumor activity … “
=======================================
=======================================
[8] – ANTINEOPLASTON THERAPY, HS-183, pg. 2
=======================================
=======================================
“After the reviewers found some evidence of antitumor activity … “
=======================================
=======================================
These facts indicate to me that the American Cancer Society’s claim about “antineoplastons”, is “debatable”

Maybe they should have learned how to use the Freedom of Information Act (FOIA)
=======================================
REFERENCES:
=======================================
[1]
——————————————————————
http://m.cancer.org/treatment/treatmentsandsideeffects/complementaryandalternativemedicine/pharmacologicalandbiologicaltreatment/antineoplaston-therapy
=======================================
[6]
——————————————————————
http://www.emory.edu/KomenEd/PDF/Treatment/Antineoplastons.pdf
=======================================
[7]
——————————————————————
https://www.bcbsal.org/providers/policies/final/280.pdf
=======================================
[8]
——————————————————————
https://www.wellcare.com/WCAssets/corporate/assets/HS183_Antineoplaston_Therapy.pdf
=======================================